UBS Group
GBT

UBS Group’s Global Blood Therapeutics, Inc. GBT Stock Holding History

UBS Group’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-276,847
Closed -$18.9M – 11993
2022
Q3 		$18.9M Buy
276,847
+168,360
+155% +$9.28M 0.01% 1318
2022
Q2 		$3.47M Sell
108,487
-22,618
-17% -$662K ﹤0.01% 2683
2022
Q1 		$4.54M Buy
131,105
+21,200
+19% +$634K ﹤0.01% 2625
2021
Q4 		$3.22M Sell
109,905
-35,875
-25% -$1.11M ﹤0.01% 3290
2021
Q3 		$3.71M Buy
145,780
+87,820
+152% +$2.58M ﹤0.01% 2987
2021
Q2 		$2.03M Sell
57,960
-23,171
-29% -$905K ﹤0.01% 3567
2021
Q1 		$3.31M Buy
81,131
+71,410
+735% +$3.28M ﹤0.01% 3028
2020
Q4 		$421K Buy
9,721
+7,256
+294% +$358K ﹤0.01% 4735
2020
Q3 		$136K Sell
2,465
-3,028
-55% -$192K ﹤0.01% 5020
2020
Q2 		$347K Sell
5,493
-6,142
-53% -$421K ﹤0.01% 4414
2020
Q1 		$594K Sell
11,635
-6,315
-35% -$423K ﹤0.01% 3805
2019
Q4 		$1.43M Sell
17,950
-103,815
-85% -$6.15M ﹤0.01% 3879
2019
Q3 		$5.91M Buy
121,765
+50,507
+71% +$2.63M ﹤0.01% 2222
2019
Q2 		$3.75M Buy
71,258
+47,444
+199% +$2.73M ﹤0.01% 2572
2019
Q1 		$1.26M Sell
23,814
-119,066
-83% -$5.85M ﹤0.01% 3381
2018
Q4 		$5.87M Buy
142,880
+65,783
+85% +$2.46M ﹤0.01% 2012
2018
Q3 		$2.93M Buy
77,097
+6,889
+10% +$305K ﹤0.01% 2849
2018
Q2 		$3.17M Sell
70,208
-66,186
-49% -$3.01M ﹤0.01% 2744
2018
Q1 		$6.59M Buy
136,394
+102,351
+301% +$5.71M ﹤0.01% 2063
2017
Q4 		$1.34M Sell
34,043
-38,127
-53% -$1.42M ﹤0.01% 3525
2017
Q3 		$2.24M Buy
72,170
+6,827
+10% +$192K ﹤0.01% 3028
2017
Q2 		$1.79M Buy
65,343
+28,120
+76% +$837K ﹤0.01% 3126
2017
Q1 		$1.37M Buy
+37,223
New +$937K ﹤0.01% 3271
2016
Q3 		– Sell
-128,813
Closed -$2.14M – 8041
2016
Q2 		$2.14M Sell
128,813
-3,396
-3% -$68.5K ﹤0.01% 2728
2016
Q1 		$2.1M Sell
132,209
-83,222
-39% -$1.48M ﹤0.01% 2630
2015
Q4 		$6.96M Buy
+215,431
New +$9.33M ﹤0.01% 1693

Other funds holding GBT

BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

UBS Group's GBT Position: Q4 2022 in Review

UBS Group sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 276,847 shares — an estimated $18.9M sold.

UBS Group first reported a position in GBT in Q4 2015 and held it in 26 quarters. The position peaked at $18.9M in Q3 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

  • UBS Group reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
  • UBS Group sold 276,847 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $18.9M.
  • UBS Group first reported a position in Global Blood Therapeutics, Inc. in Q4 2015 and held it in 26 quarters.
  • UBS Group's Global Blood Therapeutics, Inc. position peaked at $18.9M in Q3 2022.
  • 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on UBS Group's 13F filing for Q4 2022, filed 8 Feb 2023.